



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Lehmann-Lintz, T. et al)

Art Unit: Examiner:

1624

Serial No.:

10/089,024

Conf. No.: Filed:

5481

Tileu

07/01/2002

For:

Substituted Piperazine Derivatives, The Production And Use Thereof

As Medicaments

Docket No.:

5/1272US

Office of Initial Patent Examination's Customer Service Center Commissioner for Patents Washington, DC 20231

September 23, 2002

RECEIVED

NOV 0 1 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The undersigned respectfully requests correction of the Filing Receipt for Application Number 10/089,024, Confirmation No. 5481.

Please correct the spelling of the fourth named applicant from "Micheal Mark" to –Michael Mark--, as noted on the attached copy of the Official Filing Receipt.

The undersigned hereby requests that the United States Patent and Trademark Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Anthony P. Bottino

Attorney for Applicant(s)

Reg. No. 41,629

SEP 3 0 2002 SEP 3 Patent

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877

Tel.: (203) 791-6764

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on September 23, 2002

By: Anthony P. Bottino

Reg. No. 41,629

RECEIVED
NOV 0 1 2002

TECH CENTER 1600/2900



United States Patent and Trademark Office

Page 1 of 2

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

www.uspła.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 10/089.024
 07/01/2002
 1624
 1430
 5/1272US
 11
 2

CONFIRMATION NO. 5481

28505 BOEHRINGER INGELHEIM CORPORATION 900 RIDGEBURY ROAD P. O. BOX 368 RIDGEFIELD, CT 06877



FILING RECEIPT

-0C000000008531383*

Date Mailed: 07/30/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested correction (if appropriate).

Applicant(s)

Thorsten Lehmann-Lintz, Ochsenhausen, GERMANY; Armin Heckel, Biberach, GERMANY; Leo Thomas, Biberach, GERMANY; Micheal Mark, Biberach, GERMANY;

Michael Mark

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP00/09146 09/19/2000

Foreign Applications

GERMANY 19945594.5 09/23/1999

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

DECEIVE AUG - 5 2002 PATENT SECTION

RECEIVED

NOV 0 1 2002

TECH CENTER 1600/2900

RECEIVED

Substituted piperazine derivatives, the production and use thereof as medicaments

AUG - 3 2002 ANTHONY BOTTINO

COPY

Titl

Preliminary Class

544

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

